RxDoctor Payments Data

Jordan Chaisson, MD

Clinical Cardiac Electrophysiology · Mobile, ALNPI 1871869990

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (43.7%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Abbott at 35.6% of the total. Reporting peaked in 2019 at $30,123 and has fallen 96.4% since, to $1,076 in 2025.

$46,497in general payments, 2019–2025

Across 508 payments — averaging $91.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$17K
  • Medtronic$15K
  • Boston Scientific$7K
  • Biotronik Inc.$3K
  • Biosense Webster, Inc.$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$864
  • plus $3K from 23 others

What the payments were for

  • Grants$16,25035%
  • Travel & lodging$9,03319%
  • Food & beverage$20,29744%
  • Education$9162%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,497 in reported general payments places this provider in the 75th percentile of 42 clinical cardiac electrophysiology providers in Alabama.

See all clinical cardiac electrophysiology providers in Alabama

Medicare billing

Part B allowed, 2024
$429,731
Medicare patients
2,425
Services billed
6,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban835$836,628
EntrestoSacubitril/Valsartan185$196,327
XareltoRivaroxaban162$166,718
MultaqDronedarone Hcl91$82,272
JardianceEmpagliflozin35$31,541
FarxigaDapagliflozin Propanediol15$19,126
Repatha SureclickEvolocumab19$15,635
Dofetilide118$12,161
Metoprolol Succinate484$7,074
Dilt-XrDiltiazem Hcl95$3,163
Flecainide Acetate45$2,897
Diltiazem 12hr ErDiltiazem Hcl19$2,752
Carvedilol294$2,574
Amiodarone Hcl147$2,572
Diltiazem 24hr Er (Cd)Diltiazem Hcl82$2,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$836,628835 claims
NovartisEntresto$301$196,327185 claims
Johnson & JohnsonXarelto$439$166,718162 claims
Sanofi-aventis U.S. LLCMultaq$21$82,27291 claims
AstraZenecaFarxiga$169$19,12615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 42 clinical cardiac electrophysiology providers in Alabama.

Other clinical cardiac electrophysiology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →